How is rapamycin dosed?
| Form | Strength as labelled |
|---|---|
| Tablet | 0.5 mg, 1 mg and 2 mg1 |
| Oral solution | 1 mg/mL, one 60 mL amber bottle with oral syringes3 |
| Topical gel (Hyftor) | 0.2%, which is 2 mg per gram, in 10 g tubes4 |
Sirolimus tablets come in 0.5 mg, 1 mg and 2 mg, and the label, written for kidney-transplant rejection prophylaxis and lymphangioleiomyomatosis (LAM), gives them by mouth once daily; in the 48-week PEARL trial (Moel et al., 2025), healthy, normative-aging adults took placebo, 5 mg or 10 mg of compounded rapamycin once a week, and 114 completed.12
Tablet strengths and other forms
Powder and oral solution
A DailyMed search found no label or maker's leaflet on mixing rapamycin powder in water. The solution leaflet says to empty the syringe into a glass or plastic cup holding at least 2 ounces (60 mL) of water or orange juice, stir for 1 minute and drink right away.3 It then says to rinse the cup with at least 4 ounces (120 mL) more of water or orange juice and drink that, and not to mix the solution with apple juice, grapefruit juice or other liquids.3
What the label gives for dose and stepping
The label's patient leaflet says sirolimus is taken by mouth 1 time each day and tablets are not crushed, chewed or split.1 It also says the doctor may change the dose depending on blood test results.1
How often levels are checked
The leaflet says the doctor checks the levels of sirolimus in the blood.1 In the 26-week open-label Alzheimer's pilot (Wallgren et al.) of 13 people with early-stage Alzheimer's disease, blood concentrations were measured during week 13 at pre-dose and 1-, 3-, and 48-h post-dose.5
Doses in human trials
The PEARL authors describe low-dose intermittent rapamycin as commonly given at 3 to 10 mg per week of standard commercial formulations or the equivalent.2
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| PEARL (Moel et al., 2025) | 5 mg or 10 mg compounded rapamycin once a week, or placebo2 | Healthy, normative-aging adults; 114 completed, 11 discontinued; per-arm numbers not in the saved text2 | 48 weeks2 |
| RAPA-EX-01 (Stanfield et al., 2026) | Sirolimus 6 mg once a week, or placebo, 24 hours after the week's last exercise session6 | 40 sedentary adults aged 65 to 856 | 13‐week home-based strength and endurance programme6 |
| Alzheimer's pilot (Wallgren et al.), open label | Weekly doses, starting at 3 mg and raised to 7 mg in the second week if well tolerated, as 1 mg Rapamune tablets; 11 took 7 mg and 2 took 2 mg or 4 mg5 | 13 people with early-stage Alzheimer's disease5 | 26 weeks5 |
| Healthy-adult pilot (Kraig et al.) | 1 mg rapamycin daily, or placebo7 | 25 generally healthy adults aged 70 to 95; 11 on rapamycin and 14 on placebo completed at least 8 weeks7 | Phase 1 (ages 80 to 95) 4 months as tolerated, phase 2 two months7 |
| Cardiac-rehab pilot (Singh, 2016) | 0.5 mg (6 people), 1.0 mg (6) or 2 mg (1) oral rapamycin daily8 | 13 older adults with coronary artery disease in cardiac rehabilitation8 | 12 weeks8 |
The PEARL authors report that, in an independent cohort studied while the trial was paused, compounded rapamycin gave approximately ⅓ the blood concentration of commercial rapamycin after 24 hours, so equivalent effective doses of the compounded form are approximately 66% less than the listed dose.2 A registry entry (NCT06550271) for a completed retrospective observational study lists compounded rapamycin at 5, 10, or 15 mg once per week and generic rapamycin at 2, 3, 6, or 8 mg once per week.9
Storage
The label stores tablets at 20°C to 25°C and has them dispensed in a tight, light-resistant container.1 It stores oral solution bottles refrigerated at 2°C to 8°C and protected from light, and says the contents are used within one month once the bottle is open.3 The patient leaflet says solution bottles can be kept at room temperature up to 25°C for up to 15 days if necessary, and solution in a syringe at room temperature up to 25°C or in the refrigerator at 2°C to 8°C for up to 24 hours.3 The Hyftor label stores the gel refrigerated at 2° to 8°C, protected from light.4
Frequently asked questions
Is rapamycin labelled for longevity or anti-aging?
The tablet label indicates sirolimus for the prophylaxis of organ rejection in patients aged 13 years or older receiving kidney transplants and for the treatment of lymphangioleiomyomatosis (LAM), and lists no longevity or anti-aging use.1
Is there a label for a homemade rapamycin cream?
A DailyMed search for Hyftor and sirolimus gel turned up no label or trial for a homemade or compounded rapamycin cream. The Hyftor label, for facial angiofibroma associated with tuberous sclerosis in adults and children 6 years of age and older, applies the gel to the affected facial skin twice daily.4
What do sources say about rapamycin cycles?
Checks of PubMed and the trial registry turned up no human trial of on and off blocks of rapamycin. A review raises a theoretical concern about rebound mTOR activity with intermittent dosing and says no longer-term data exist to clarify it.10
- Rapamycin (sirolimus)The compound page with half-life and trial results.
- SupplementsMore supplement compounds.
- Units and dosingUnits, syringe marks and dosing maths.
- How to take creatine monohydrateDosing guide for a supplement powder.
- Cholecalciferol dosageAnother supplement dosing guide.
- Omega-3 fish oil dosageAnother supplement dosing guide.
References
- Mylan Pharmaceuticals (DailyMed). These highlights do not include all the information needed to use SIROLIMUS safely and effectively. See full prescribing information for SIROLIMUS. SIROLIMUS tablets, for oral use Initial U.S. Approval: 1999. 2026. dailymed.nlm.nih.gov
- PMC. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. 2025. pmc.ncbi.nlm.nih.gov
- Mylan Pharmaceuticals (DailyMed). These highlights do not include all the information needed to use SIROLIMUS safely and effectively. See full prescribing information for SIROLIMUS. SIROLIMUS oral solution Initial U.S. Approval: 1999. 2026. dailymed.nlm.nih.gov
- Nobelpharma America (DailyMed). These highlights do not include all the information needed to use HYFTOR ® safely and effectively. See full prescribing information for HYFTOR. HYFTOR ® (sirolimus topical gel) Initial U.S. Approval: 1999. 2025. dailymed.nlm.nih.gov
- PMC. Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease. 2025. pmc.ncbi.nlm.nih.gov
- PMC. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. 2026. pmc.ncbi.nlm.nih.gov
- PMC. A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort: Immunological, Physical Performance, and Cognitive Effects. 2018. pmc.ncbi.nlm.nih.gov
- PubMed. Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study. 2016. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT06550271: The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals. 2023. clinicaltrials.gov
- PMC. What is the clinical evidence to support off-label rapamycin therapy in healthy adults?. 2025. pmc.ncbi.nlm.nih.gov